-
Citi Opens 90-Day Positive Catalyst Call on Olema Pharmaceuticals (OLMA)
-
Olema Pharmaceuticals (OLMA) PT Raised to $60 at Citi, Opens Catalyst Watch
-
Olema Pharmaceuticals (OLMA) files mixed shelf
-
Olema Pharmaceuticals (OLMA) PT Raised to $45 at H.C. Wainwright
-
Olema Pharmaceuticals (OLMA) PT Raised to $38 at Goldman Sachs
-
Olema Pharmaceuticals (OLMA) PT Raised to $43 at Jefferies
-
Olema Pharmaceuticals (OLMA) halted on volatility, up 167%
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Guggenheim Starts Olema Pharmaceuticals (OLMA) at Buy
-
Olema Pharmaceuticals (OLMA) latest collaboration could create future 'bidding war' - Oppenheimer
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Olema Oncology partners with Pfizer for breast cancer drug trial
-
Olema Pharmaceuticals (OLMA) PT Raised to $21 at Citi, Opens Catalyst Watch
-
Olema Pharmaceuticals, Inc. (OLMA) Misses Q2 EPS by 13c
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Olema Pharmaceuticals (OLMA) PT Lowered to $28 at H.C. Wainwright
-
Olema Pharmaceuticals, Inc. (OLMA) Tops Q1 EPS by 18c
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Olema Pharmaceuticals, Inc. (OLMA) Tops Q4 EPS by 13c
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Olema Pharmaceuticals (OLMA) Files $200M Mixed Shelf
-
Olema Pharmaceuticals (OLMA) option IV near upper end of range
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Olema Pharmaceuticals (OLMA) Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
-
TD Cowen Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Jefferies Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
H.C. Wainwright Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Goldman Sachs Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
-
Goldman Sachs Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)

